Translational research and drug screening
The pharmaceutical industry find the competencies within pain research and drug screening at the Department of Health Science and Technology's Center for Sensory-Motor Interaction SMI® very attractive. The research comprises translational research from basic animal research to human clinical tests resulting in new applications and products that can be of great interest to industry.
The pain assessment technologies of SMI® make it possible to screen and test the effect of new pain-relieving procedures and drugs at an early stage in the development process. This can provide mechanism-based proof-of-concept studies and can help target the patient populations investigated in phase II and III clinical trials. Early experimental volunteer studies can provide information on mechanisms of action, efficient doses, and pharmacy dynamics. Such trials can help companies develop programs leading to cost efficient processes.
In all patient studies our quantitative pain assessment technologies are used together with clinical parameters.